2Saraf S, Wellstod D, Sharma S, et al. Shear-induced global thrombosis test of native blood: Pivotal role of ADP allows monitoring of P2Y12 antagonist therapy [J]. Thrombosis Research, 2009, 124(4) :447.
3Hoffmann K, Sixel U, Pasquale FD, et al. Involvement of basic amino acidresidues in transmembrane regions 6 and 7 in agnnist and antagonist recognition of the human platelet P2Y12-reeeptor[J]. Biochemical Pharmacology, 2008, 76 (10) : 1201.
4Bonello L, Bonello-Palot N, Armero S, et al. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients [J]. Thrombosis Research, 2009.
5Lepatalo A, Virtanen A S, Resendiz J C, et al. Antiplatelet effect ofclopidogrelin patients with aspirin therapy undergoing pereutaneous coronary interventions-Limited inhibition of the P2Y12 receptor[J]. Thrombosis Research, 2009, 124: 193.
6Farid N A, Smith R L, Gillespie T A, et al. The disposition of prasugrel, a novel thienopyridine in humans[J], drug Metab Dispos, 2007, 35: 1096.
7Ogawa T, Hashimoto M, Niitsu Y, et al. Effects of prasugrel, a novel P2Y12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseases[J]. European journal of pharmacology, 2009, 612: 29.
8Angiolillo D, Bates E, Bass T. Clinical profile of prasugrel, a novel thienopyridine[J]. American Heart Journal, 2008, 156(2) :S16.
9Antman E, Wiviott S, Murphy S, etal, Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention[J]. Journal of the American College of Cardiology, 2008, 51 (21): 2028.
10Post J M, Alexander S, Wang Y X, et al. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (Ⅱ): Phatmacodynamic and pharmaco kinetic characterization [J]. Thrombosis Research, 2008, 122 (4): 533.
